From GlobeNewswire: 2025-05-06 01:00:00

In the first quarter of 2025, Royal Philips reported group sales of EUR 4.1 billion, a 2% decline in comparable sales mainly due to China. Despite this, income from operations increased to EUR 154 million, with an adjusted EBITA margin of 8.6% of sales. Philips remains focused on serving customers, driving growth, and delivering better care. The company is improving supply chain agility and taking cost actions to mitigate financial impact. Philips introduced new AI technologies to enhance patient outcomes and signed partnerships to modernize workflows. Productivity initiatives have delivered savings of EUR 147 million in Q1, on track to achieve EUR 800 million in 2025. The company’s outlook for 2025 includes the impact of tariffs, with an unchanged sales growth outlook of 1%-3% and an adjusted EBITA margin range of 10.8%-11.3%. Free cash flow is expected to be slightly positive for the full year. Philips anticipates performance will improve in the latter part of the year, excluding ongoing Respironics-related proceedings.

For further information, contact Michael Fuchs at Philips Global External Relations (Tel.: +31 6 1486 9261, E-mail: [email protected]) or Dorin Danu at Philips Investor Relations (Tel.: +31 20 59 77055, E-mail: [email protected]). Royal Philips is a leading health technology company focused on improving people’s health through innovation. The company generated sales of EUR 18 billion in 2024 and employs approximately 67,200 people worldwide. News about Philips can be found at www.philips.com/newscenter.

The outlook for Philips in 2025 includes the assumed impact of tariffs, with an unchanged sales growth outlook of 1%-3% and an adjusted EBITA margin range of 10.8%-11.3%. The company anticipates a slightly positive free cash flow for the year, skewed towards the latter part of 2025.



Read more at GlobeNewswire: Philips delivers on Q1 results, with ongoing order intake